OCT 50
Alternative Names: OCT-50Latest Information Update: 03 Dec 2024
Price :
$50 *
At a glance
- Originator Octagon Therapeutics
- Class Monoclonal antibodies
- Mechanism of Action CD22 antigen inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Autoimmune disorders; Cutaneous lupus erythematosus; Multiple sclerosis; Sjogren's syndrome; Systemic lupus erythematosus
Most Recent Events
- 03 Sep 2024 Preclinical trials in Autoimmune disorders in USA (Parenteral) (Octagon Therapeutics pipeline, September 2024)
- 03 Sep 2024 Preclinical trials in Cutaneous lupus erythematosus in USA (Parenteral) (Octagon Therapeutics pipeline, September 2024)
- 03 Sep 2024 Preclinical trials in Multiple sclerosis in USA (Parenteral) (Octagon Therapeutics pipeline, September 2024)